Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5009929 | 0.99 | ALDH1A1 (0.62) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5013682 | 0.97 | ALDH1A1 (0.55) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL8060168 | 0.88 | ITGB1 (0.57) | ALDH1A1POLBSLC7A5PTPN1MAPT | |
| SCHEMBL21690440 | 0.88 | KMT2A (0.58) | ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1 | |
| SCHEMBL8058266 | 0.88 | PTPN1 (0.47) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2857963 | 0.88 | ITGB1 (0.57) | ALDH1A1POLBSLC7A5PTPN1MAPT | |
| SCHEMBL8058263 | 0.88 | PTPN1 (0.47) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL21689918 | 0.88 | KMT2A (0.58) | ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1 | |
| SCHEMBL17822347 | 0.85 | ALDH1A1 (0.55) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL17822346 | 0.85 | ALDH1A1 (0.55) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940827-A1 | CARBAMATE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals Inc. (US) | 2008-07-09 | — | — | EP | claimed |
| EP-1940826-A1 | PYRIMIDINYL AMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals Inc. (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2007041270-A1 | PYRIMIDINYL AMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-12 | — | — | WO | claimed |
| WO-2007041324-A1 | CARBAMATE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-12 | — | — | WO | claimed |
| WO-2025106386-A1 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250152658-A1 | CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2025-05-15 | — | — | US | disclosed |
| EP-2231185-A1 | METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS | Elan Pharmaceuticals Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009075806-A1 | METHODS AND COMPOSITIONS FOR TREATING LIQUID TUMORS | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| EP-2007392-A2 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4 INHIBITORY COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1940827-A1 | CARBAMATE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007100763-A2 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4 INHIBITORY COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007041324-A1 | CARBAMATE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152658-A1 | CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | IL1R1, IL1A, IL1B | ALDH1A1 1340/4885POLB 3499/4885SMN1; SMN2 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.